JP2018535948A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535948A5
JP2018535948A5 JP2018518592A JP2018518592A JP2018535948A5 JP 2018535948 A5 JP2018535948 A5 JP 2018535948A5 JP 2018518592 A JP2018518592 A JP 2018518592A JP 2018518592 A JP2018518592 A JP 2018518592A JP 2018535948 A5 JP2018535948 A5 JP 2018535948A5
Authority
JP
Japan
Prior art keywords
seq
lepr
antigen
binding fragment
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018518592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535948A (ja
JP7034068B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/056465 external-priority patent/WO2017066204A1/en
Publication of JP2018535948A publication Critical patent/JP2018535948A/ja
Publication of JP2018535948A5 publication Critical patent/JP2018535948A5/ja
Application granted granted Critical
Publication of JP7034068B2 publication Critical patent/JP7034068B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018518592A 2015-10-12 2016-10-11 レプチン受容体を活性化させる抗原結合タンパク質 Active JP7034068B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562240021P 2015-10-12 2015-10-12
US62/240,021 2015-10-12
US201662359757P 2016-07-08 2016-07-08
US62/359,757 2016-07-08
US201662375495P 2016-08-16 2016-08-16
US62/375,495 2016-08-16
US201662393143P 2016-09-12 2016-09-12
US62/393,143 2016-09-12
PCT/US2016/056465 WO2017066204A1 (en) 2015-10-12 2016-10-11 Antigen-binding proteins that activate the leptin receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021039405A Division JP7165225B2 (ja) 2015-10-12 2021-03-11 レプチン受容体を活性化させる抗原結合タンパク質

Publications (3)

Publication Number Publication Date
JP2018535948A JP2018535948A (ja) 2018-12-06
JP2018535948A5 true JP2018535948A5 (https=) 2019-11-21
JP7034068B2 JP7034068B2 (ja) 2022-03-11

Family

ID=57184864

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018518592A Active JP7034068B2 (ja) 2015-10-12 2016-10-11 レプチン受容体を活性化させる抗原結合タンパク質
JP2021039405A Active JP7165225B2 (ja) 2015-10-12 2021-03-11 レプチン受容体を活性化させる抗原結合タンパク質
JP2022169008A Active JP7436603B2 (ja) 2015-10-12 2022-10-21 レプチン受容体を活性化させる抗原結合タンパク質
JP2023202680A Active JP7699191B2 (ja) 2015-10-12 2023-11-30 レプチン受容体を活性化させる抗原結合タンパク質
JP2024018406A Active JP7759417B2 (ja) 2015-10-12 2024-02-09 レプチン受容体を活性化させる抗原結合タンパク質

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2021039405A Active JP7165225B2 (ja) 2015-10-12 2021-03-11 レプチン受容体を活性化させる抗原結合タンパク質
JP2022169008A Active JP7436603B2 (ja) 2015-10-12 2022-10-21 レプチン受容体を活性化させる抗原結合タンパク質
JP2023202680A Active JP7699191B2 (ja) 2015-10-12 2023-11-30 レプチン受容体を活性化させる抗原結合タンパク質
JP2024018406A Active JP7759417B2 (ja) 2015-10-12 2024-02-09 レプチン受容体を活性化させる抗原結合タンパク質

Country Status (31)

Country Link
US (6) US10023644B2 (https=)
EP (2) EP3362477B1 (https=)
JP (5) JP7034068B2 (https=)
KR (2) KR20250069979A (https=)
CN (1) CN108368177B (https=)
AU (2) AU2016338851B2 (https=)
CA (1) CA3000215A1 (https=)
CL (2) CL2018000946A1 (https=)
CO (1) CO2018003852A2 (https=)
CY (1) CY1125102T1 (https=)
DK (1) DK3362477T3 (https=)
EA (1) EA201890928A1 (https=)
ES (1) ES2908574T3 (https=)
HR (1) HRP20220426T8 (https=)
HU (1) HUE058280T2 (https=)
IL (3) IL316563A (https=)
LT (1) LT3362477T (https=)
MX (2) MX2018004531A (https=)
MY (1) MY187975A (https=)
PH (1) PH12018500663A1 (https=)
PL (1) PL3362477T3 (https=)
PT (1) PT3362477T (https=)
RS (1) RS63061B1 (https=)
SG (1) SG10201913432RA (https=)
SI (1) SI3362477T1 (https=)
SM (1) SMT202200125T1 (https=)
TW (3) TW202417497A (https=)
UA (1) UA124419C2 (https=)
UY (1) UY36942A (https=)
WO (1) WO2017066204A1 (https=)
ZA (1) ZA201801975B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107635527B (zh) 2015-03-10 2021-04-23 里珍纳龙药品有限公司 无菌刺穿系统和方法
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
LT3538554T (lt) * 2016-11-08 2025-10-10 Antigeną surišantys baltymai, antagonizuojantys leptino receptorius
IL308643B2 (en) 2017-05-05 2025-02-01 Regeneron Pharma Auto-injector
SG11202005146VA (en) * 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
JP7328982B2 (ja) * 2018-10-11 2023-08-17 住友化学株式会社 プロピレンオキサイド精製装置、及び、プロピレンオキサイドの製造方法
WO2020160199A1 (en) * 2019-01-31 2020-08-06 Siemens Healthcare Diagnostics Inc. Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
US20220288169A1 (en) * 2019-05-24 2022-09-15 The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College Compositions and methods for the treatment and prevention of hypoglycemic complications
GB2600273B (en) * 2019-07-02 2024-06-05 Univ Shanghai Technology Antibody to leptin receptor
US11392515B2 (en) 2019-12-03 2022-07-19 Micron Technology, Inc. Cache architecture for a storage device
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR20230069969A (ko) * 2020-09-15 2023-05-19 리제너론 파마슈티칼스 인코포레이티드 통증에 대한 lepr 아고니스트의 사용
EP4294257B1 (en) 2021-02-22 2025-11-05 Regeneron Pharmaceuticals, Inc. Method for diagnosing and treating partial lipodystrophy
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
CN114456124B (zh) * 2021-12-30 2023-04-21 华南农业大学 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用
CN121548440A (zh) 2023-06-16 2026-02-17 里珍纳龙药品有限公司 医疗装置包装及相关方法
WO2025075970A1 (en) 2023-10-02 2025-04-10 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
TW202602926A (zh) 2024-03-15 2026-01-16 美商美國禮來大藥廠 作為治療肥胖症之單一或組合療法之瘦素受體促效抗體
WO2025227054A1 (en) * 2024-04-25 2025-10-30 The Board Of Regents Of The University Of Texas System Monoclonal antibodies binding to leptin and uses thereof
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US6977240B1 (en) * 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
AU721129B2 (en) 1996-01-08 2000-06-22 Genentech Inc. WSX receptor and ligands
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
WO1997027286A1 (en) 1996-01-23 1997-07-31 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
AU2002359288B2 (en) 2001-10-22 2008-07-31 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
CN1630514A (zh) * 2001-12-05 2005-06-22 贝勒医学院 通过调节交感神经紧张性控制骨形成的方法和组合物
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
DE10353593A1 (de) * 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US20070281327A1 (en) * 2003-12-12 2007-12-06 Kiyotaka Nakano Methods of Screening for Modified Antibodies With Agonistic Activities
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
WO2009045900A2 (en) 2007-09-28 2009-04-09 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing diseases associated with low bone mass
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
KR20130118941A (ko) 2011-02-10 2013-10-30 로슈 글리카트 아게 면역치료법
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
MX2014014891A (es) 2012-06-05 2015-06-17 Regeneron Pharma Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun.
PL3366705T3 (pl) 2012-09-12 2023-09-18 Genzyme Corporation FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US20170051062A1 (en) 2014-02-18 2017-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
LT3538554T (lt) 2016-11-08 2025-10-10 Antigeną surišantys baltymai, antagonizuojantys leptino receptorius
CN107760761A (zh) 2017-11-10 2018-03-06 江苏省农业科学院 一种加强瘦素激发lepr信号转导的方法
SG11202005146VA (en) 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia

Similar Documents

Publication Publication Date Title
JP2018535948A5 (https=)
CN106068125B (zh) 治疗脂肪组织积聚的组合物和方法
JP2011506483A5 (https=)
US20230233675A1 (en) Methods, regimens, combinations & antagonists
CN102027015A (zh) 抗cxcr4抗体
RU2014117510A (ru) Лечение ревматоидного артрита
JP2021525718A5 (https=)
WO2016122996A1 (en) Vegfa/ang2 compounds
JP2022513421A5 (https=)
KR20250122524A (ko) 미오스타틴 활성화의 선택적이고 강력한 억제 항체
JP2022547452A (ja) Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療
CA3169994A1 (en) Methods for the treatment of scleroderma and related conditions
KR20250084991A (ko) 항-FcRN 항체를 이용한 만성 염증성 탈수초성 다발성 신경병증의 치료 방법
CN111886252A (zh) 促进胰岛细胞生长的方法
JP2022520107A5 (https=)
EP3145544B1 (en) Ang2 antibodies
AU2009322587B2 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
JP2009538916A5 (https=)
CA2638869A1 (en) Humanized anti-ghrelin antibodies
TWI454481B (zh) 結合ＴＧＦ－α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體
JP2018533588A (ja) 治療パラダイム
EP4584294A1 (en) Methods of treating graves' disease using anti-fcrn antibodies
CN119584995A (zh) 组合疗法
JP2023539107A5 (https=)
JP2010540660A5 (https=)